The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
9,295
Sort by:
The 2027-2032 World Outlook for Myasthenia Gravis
US$ 1,195.00
This study covers the world outlook for myasthenia gravis across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), fo...
January 2026
287 pages
The 2027-2032 World Outlook for Myasthenia Gravis Drugs
US$ 1,195.00
This study covers the world outlook for myasthenia gravis drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E...
January 2026
287 pages
The 2027-2032 World Outlook for Myasthenia Gravis Treatments
US$ 1,195.00
This study covers the world outlook for myasthenia gravis treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (...
January 2026
288 pages
The 2027-2032 World Outlook for Narcolepsy Drugs
US$ 1,195.00
This study covers the world outlook for narcolepsy drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for...
January 2026
287 pages
The 2027-2032 World Outlook for Nasal Polyps Treatments
US$ 1,195.00
This study covers the world outlook for nasal polyps treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E...
January 2026
287 pages
The 2027-2032 World Outlook for Nasal Sprays
US$ 1,195.00
This study covers the world outlook for nasal sprays across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the...
January 2026
287 pages
The 2027-2032 World Outlook for Neonatal Jaundice Treatments
US$ 1,195.00
This study covers the world outlook for neonatal jaundice treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (...
January 2026
288 pages
The 2027-2032 World Outlook for Neurodegenerative Diseases
US$ 1,195.00
This study covers the world outlook for neurodegenerative diseases across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P....
January 2026
288 pages
The 2027-2032 World Outlook for Neurodegenerative Disorders
US$ 1,195.00
This study covers the world outlook for neurodegenerative disorders across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P...
January 2026
288 pages
The 2027-2032 World Outlook for Neurological Disorder Drugs
US$ 1,195.00
This study covers the world outlook for neurological disorder drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P...
January 2026
288 pages
The 2027-2032 World Outlook for Neuropathic Pain Management
US$ 1,195.00
This study covers the world outlook for neuropathic pain management across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P...
January 2026
288 pages
The 2027-2032 World Outlook for Neuroprotection Therapeutics
US$ 1,195.00
This study covers the world outlook for neuroprotection therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (...
January 2026
288 pages
The 2027-2032 World Outlook for Neuroprotective Agents
US$ 1,195.00
This study covers the world outlook for neuroprotective agents across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E....
January 2026
287 pages
The 2027-2032 World Outlook for Non-Opioid Pain Patches
US$ 1,195.00
This study covers the world outlook for non-opioid pain patches across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E...
January 2026
287 pages
The 2027-2032 World Outlook for Non-Opioid Pain Treatments
US$ 1,195.00
This study covers the world outlook for non-opioid pain treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P....
January 2026
288 pages
The 2027-2032 World Outlook for Omeprazole
US$ 1,195.00
This study covers the world outlook for omeprazole across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the c...
January 2026
287 pages
The 2027-2032 World Outlook for Opioid Drugs
US$ 1,195.00
This study covers the world outlook for opioid drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the...
January 2026
287 pages
The 2027-2032 World Outlook for Opioid Use Disorders
US$ 1,195.00
This study covers the world outlook for opioid use disorders across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.),...
January 2026
287 pages
The 2027-2032 World Outlook for Oral Alopecia Drugs
US$ 1,195.00
This study covers the world outlook for oral alopecia drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.),...
January 2026
287 pages
The 2027-2032 World Outlook for Oral Anti Diabetes Drugs
US$ 1,195.00
This study covers the world outlook for oral anti diabetes drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I....
January 2026
287 pages
The 2027-2032 World Outlook for Oral Iron Drugs
US$ 1,195.00
This study covers the world outlook for oral iron drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for...
January 2026
287 pages
The 2027-2032 World Outlook for Oral Proteins and Peptides
US$ 1,195.00
This study covers the world outlook for oral proteins and peptides across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P....
January 2026
287 pages
The 2027-2032 World Outlook for Orphan Biologic Drugs
US$ 1,195.00
This study covers the world outlook for orphan biologic drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.)...
January 2026
288 pages
The 2027-2032 World Outlook for Osteoarthritis Drugs
US$ 1,195.00
This study covers the world outlook for osteoarthritis drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.),...
January 2026
287 pages
The 2027-2032 World Outlook for Osteoarthritis Therapeutics
US$ 1,195.00
This study covers the world outlook for osteoarthritis therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P...
January 2026
287 pages
